Product Type: Inhibitor
CAS No.: 1187594-09-7
MolecularFormula: C16H17N7O2S
Molecular Weight: 371,4
Source: Synthetic
Purity: >98% (HPLC); NMR (Conforms)
Solubility: May be dissolved in DMSO (30 mg/ml); or DMF (50 mg/ml)
Appearance: White to off-white powder
PubChem CID: 44205240
Scientific Background: Baricitinib acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2, therby reducing cytokine release and suppressing the innate and adaptive immune systems. It was recently shown to significantly improve COVID-19 symptoms in a preliminary human trial, presumably through suppression of the cytokine release syndrome (“cytokine storm”) induced by SARS-CoV-2 infection.
References: 1."Summary of opinion for Olumiant" (PDF). European Medicines Agency (EMA). 15 December 2016. 2. Cantini F., et al. (2020) J. Infect. DOI: 10.1016/j.jinf.2020.04.017
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
Deutsch
English
